ArticleFrontiers in cardiovascular medicine2026
Outcomes for acute myocardial infarction with supranormal left ventricular ejection fraction.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aims: Despite cumulative evidence of superior outcomes for acute myocardial infarction (AMI) with normal left ventricular ejection fraction (LVEF) compared to those for AMI with reduced LVEF, real-world evidence on outcomes of patients with AMI and supranormal LVEF (snLVEF) is lacking. Therefore, this study aimed to evaluate the clinical outcomes of patients with AMI and snLVEF. Methods: A total of 27,903 patients with AMI were included from the Korean nationwide AMI cohort between November 2011 and June 2020 after excluding those with unmeasurable LVEF. Patients were classified into four groups according to LVEF: supranormal (≥65%), normal (50%-64%), mid-range (40%-49%), and reduced (<40%). The primary outcome was 3-year all-cause mortality. Results: Across four hierarchical Cox models, snLVEF was consistently associated with lower 3-year all-cause mortality compared with normal LVEF (a crude model HR 0.71; 95% CI 0.58-0.87; a fully-adjusted model HR 0.77; 95% CI 0.60-0.98), with similar estimates observed in intermediate models. Conclusions: Patients with AMI and snLVEF experienced the best clinical outcomes with the lowest mortality across the four groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.